PRNewsWire
21 Sept 2026, 12:45 UTC · 1h ago
Verdict
Headline takes no side. We score ANIX +0.80 across two claims — strongly bullish.
+0.80strongly bullish
More positive than 84% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 1 new · 1 priced in
Anixa Biosciences was granted a composition-of-matter patent in Australia for its breast cancer vaccine, providing protection through 2040.
Newannounced today, Sept 21, 2026
So whatSecuring IP in additional markets increases the valuation of the asset for potential Big Pharma licensing deals in late-stage development.
More positive than 62% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
A Phase 1 trial of the breast cancer vaccine met all primary endpoints, with over 74% of participants generating protocol-defined immune responses.
Priced indescribed as a recently completed trial
So whatPositive Phase 1 data typically triggers the transition to Phase 2, which will significantly increase R&D spend in the next 12-24 months.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 84% of ticker scores this week
The company was granted a composition-of-matter patent in Australia for its breast cancer vaccine, strengthening its global IP estate and commercial potential.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
8h ago
−1.6%
Price is moving against the score
$2.73 vs $2.77 close before publication (Sep 18) · not market-adjusted
ANIX chart →
